Biohit Oyj Email Format
Biotechnology ResearchSouthwest Finland, Finland51-200 Employees
Biohit Oyj is a Finnish HealthTech company focused on biotechnology research, founded in 1988 and headquartered in Helsinki, with subsidiaries in China, Italy, and the United Kingdom. It operates globally and has been listed on the NASDAQ OMX Helsinki Small Cap Healthcare segment since 1999. The company pursues a mission of innovating for health and emphasizes social responsibility, including activities related to acetaldehyde, a recognized carcinogen in the gastrointestinal tract. Its product portfolio centers on tools for early diagnosis and risk assessment of gastrointestinal diseases, such as the blood-based GastroPanel, rapid tests for lactose intolerance and Helicobacter pylori in connection with gastroscopy, and the ColonView test for detecting fecal occult blood related to colorectal cancer risk. It also develops Acetium to reduce acetaldehyde in the GI tract. The primary customers are healthcare providers, clinics, and hospitals, and Biohit seeks distributors and licensing partners to broaden access to its diagnostics and related services.